Literature DB >> 11208653

The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.

G D Strizheva1, T Carsillo, W D Kruger, E J Sullivan, J H Ryu, E P Henske.   

Abstract

Lymphangiomyomatosis (LAM) is a progressive and often fatal interstitial lung disease characterized by a diffuse proliferation of abnormal smooth muscle cells in the lungs. LAM is of unusual interest biologically because it affects almost exclusively young women. LAM can occur as an isolated disorder (sporadic LAM) or in association with tuberous sclerosis complex (TSC). Because only a minority of women with TSC develops symptomatic LAM, we hypothesized that a relationship might exist between the type of germline TSC1 or TSC2 gene mutation and the risk of developing LAM. We examined all 41 exons of the TSC2 gene and 21 coding exons of the TSC1 gene for mutations in a group of 14 women with both TSC and LAM using single-strand conformation polymorphism analysis. Seven mutations were found in TSC2 and one in TSC1. Of the seven patients with TSC2 mutations, two had the same in-frame exon 40 deletion and one had an exon 41 missense change. We conclude that germline mutations in the extreme carboxy-terminus of tuberin can result in LAM. Further studies will be required to determine whether mutations in exons 40 and 41 are associated with an increased incidence and/or severity of LAM in women with TSC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208653     DOI: 10.1164/ajrccm.163.1.2005004

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  37 in total

1.  MRI findings reveal three different types of tubers in patients with tuberous sclerosis complex.

Authors:  Anne Gallagher; Ellen P Grant; Neel Madan; Delma Y Jarrett; David A Lyczkowski; Elizabeth A Thiele
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

Review 2.  Feasibility of immunotherapy for lymphangioleiomyomatosis.

Authors:  Michele Carbone
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 3.  Diffuse Cystic Lung Disease. Part I.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

4.  AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.

Authors:  Robert J Kaner; Kevin K Brown; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

Review 5.  New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex.

Authors:  Hilaire C Lam; Julie Nijmeh; Elizabeth P Henske
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

6.  Inactivation of Tsc2 in Abcg2 lineage-derived cells drives the appearance of polycystic lesions and fibrosis in the adult kidney.

Authors:  Leslie S Gewin; Megan E Summers; Julie W Harral; Christa F Gaskill; Stellor Nlandu Khodo; Surekha Neelisetty; Timothy M Sullivan; Katharina Hopp; J Jeffrey Reese; Dwight J Klemm; Valentina Kon; Kevin C Ess; Wei Shi; Susan M Majka
Journal:  Am J Physiol Renal Physiol       Date:  2019-08-28

7.  Lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Wendy K Steagall; Joel Moss
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2009

8.  mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.

Authors:  Jane Yu; Elizabeth Petri Henske
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

9.  Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.

Authors:  Chenggang Li; Xiaobo Zhou; Yang Sun; Erik Zhang; John D Mancini; Andrey Parkhitko; Tasha A Morrison; Edwin K Silverman; Elizabeth P Henske; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

10.  In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.

Authors:  Ling Gao; Michael M Yue; Jennifer Davis; Elisabeth Hyjek; Lucia Schuger
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.